RenovoRx, Inc., a life sciences company specializing in targeted oncology therapies, has announced the launch of the PanTheR Post-Marketing Registry Study. This multi-center, observational study aims to evaluate the long-term safety and survival outcomes of patients with solid tumors treated using the RenovoCath device for targeted drug delivery. The study will collect real-world data across diverse cancer types and clinical environments, providing insights into the device's safety and effectiveness in a real-world setting. Patient enrollment is expected to commence before the end of September 2025. The study's results have not yet been presented and will provide valuable data to inform future clinical trial designs and treatment strategies. Each participating cancer center will purchase RenovoCath devices for use in the study from RenovoRx.